Abstract

Spirulina is a phytosynthetic filamentous cyanobacterium with microscopic dimensions, which naturally grows in the highly-salted alkaline lakes of Africa, Mexico, America, and Asia. Several bioactive peptides extracted from Spirulina were demonstrated to possess antimicrobial, antiviral, antitumor, immunomodulatory, antiallergic and antihypertensive properties. It has been reported that the consumption of Spirulina could prevent or manage metabolic syndrome components. In women, metabolic disorders are more prevalent during menopause. Postmenopausal women present higher waist circumference, increased blood pressure, hypertriglyceridemia, hyperglycemia, and decreased HDL-cholesterol values, leading to an increased risk of cardiovascular events. Therefore, in order to prevent cardiovascular diseases, it is essential to manage the components of the metabolic syndrome during the postmenopausal period. As recent reports indicated the efficiency of Spirulina supplementation in the management of the metabolic syndrome components, our study aims to review all the clinical trials conducted on this topic. Our main objective is to have a better understanding of whether and how this cyanobacterium could manage the abnormalities included in the metabolic syndrome and if it could be used as a therapeutic approach in postmenopausal women with this condition. We selected relevant articles from PubMed, Google Scholar and CrossRef databases, and a total number of 20 studies met our criteria. All included clinical trials indicated that Spirulina has positive effects in managing metabolic syndrome components. Spirulina is a valuable cyanobacterium that can be used as a food supplement for the management of metabolic syndrome, and it is able to reduce the risk of cardiovascular events. The optimal dose and period of administration remain a debated subject, and future investigations are required. Considering the beneficial effects reported against each component of the metabolic syndrome, Spirulina could also be effective in the postmenopausal period, when this syndrome is the most prevalent, but there is a strong need for human clinical trials in order to sustain this observation.

Highlights

  • Spirulina, known as Arthrospira platensis, is a phytosynthetic filamentous cyanobacterium with microscopic dimensions, which showed intense biomass productivity, with the highest CO2 fixationMar

  • As recent reports indicated the efficiency of Spirulina supplementation in the management of metabolic syndrome components, our study aims to review all the clinical trials conducted on this topic

  • We included in our study all the clinical trials that pointed out the effects of this cyanobacterium on each metabolic abnormality that is part of this syndrome

Read more

Summary

Introduction

Known as Arthrospira platensis, is a phytosynthetic filamentous cyanobacterium with microscopic dimensions, which showed intense biomass productivity, with the highest CO2 fixation. Mar. Drugs 2020, 18, 651; doi:10.3390/md18120651 www.mdpi.com/journal/marinedrugs. Mar. Drugs 2020, 18, 651 rate [1]. Spirulina naturally grows in the high-salted alkaline lakes of Africa, Mexico, America and. But at present, it is commercially produced all over the world [2]. There is a large number of Spirulina species, but only three of them were intensively investigated: Spirulina platensis, Spirulina fusiformis and Spirulina maxima [3]. Spirulina has been suggested as an eco-friendly cyanobacterium, which is widely consumed as a nutritional supplement for its multiple beneficial effects on humans and animals’ health

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call